AstraZeneca (AZN) – Major News
-
Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR
-
AstraZeneca (AZN) Tops Q4 EPS by 71c; initiates guidance
-
AstraZeneca (AZN) Acquires Gracell Biotechnologies (GRCL) for $10/sh plus $1.50/sh CVR
-
Icosavax (ICVX) Acquired by AstraZeneca (AZN) for $15/sh plus Up to $5/sh CVR
-
AstraZeneca (AZN) Tops Q3 EPS by 87c; raises guidance
-
AstraZeneca (AZN) Tops Q2 EPS by $1.16, Reiterates Guidance
-
AstraZeneca (AZN) Tops Q2 EPS by 116c; reaffirms FY23 Outlook
-
AstraZeneca (AZN) Tops Q1 EPS by 20c
-
CinCor Pharma (CINC) Acquired by AstraZeneca (AZN) for $26/sh plus $10 Value Right
-
AstraZeneca (AZN) Tops Q3 EPS by 90c, Beats on Revenue
-
LogicBio Therapeutics (LOGC) Acquired by AstraZeneca (AZN) for $2.07/sh
-
AstraZeneca (AZN) Tops Q2 EPS by 93c, Beats on Revenue
-
AstraZeneca (AZN) Tops Q1 EPS by $1.06
-
AstraZeneca (AZN) Tops Q4 EPS by 94c
-
AstraZeneca (AZN) Reports Q3 Core EPS of $1.08, Revenues of $9.87B
-
AstraZeneca (AZN) Completes Acquisition of Alexion (ALXN)
-
AstraZeneca (AZN) Says Sales Surged 12% in Q4, Long-Term Growth Trends Set to Continue, Analysts Impressed
-
AstraZeneca (AZN) to Acquire Alexion Pharma (ALXN) for $39B, or $175/Share
-
AstraZeneca (AZN) confirms COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
-
AstraZeneca (AZN) Tops Q1 EPS by 12c
-
AstraZeneca (AZN) Tops Q2 EPS by 13c
-
AstraZeneca (AZN) Tops Q1 EPS by 5c
-
AstraZeneca (AZN) Tops Q4 EPS by 10c
-
AstraZeneca (AZN) Reports Q4 EPS of $1.30
-
AstraZeneca (AZN) Tops Q3 EPS by 2c
-
AstraZeneca (AZN) Posts Q2 EPS of $0.38; Reiterates Outlook
-
AstraZeneca (AZN), Merck (MRK) Enter Collaboration on Cancer Drug Lynparza; Will Receive $1.6B Upfront and Up to $8.5B
-
AstraZeneca (AZN) Shares Plunge After MYSTIC Trial Did Not Meet Primary Endpoint
-
AstraZeneca (AZN) CEO Departure Could Be Announced as Soon as Tonight - Source
-
AstraZeneca (AZN) Phase III PACIFIC Trial Shows Imfinzi Met Primary Endpoint of Statistically-Significant and Clinically-Meaningful PFS
-
AstraZeneca (AZN) Reports Q1 Core EPS of $0.99
-
AstraZeneca (AZN) Tops Q4 EPS by 8c
-
AstraZeneca (AZN) Tops Q3 EPS by 6c
-
AstraZeneca (AZN) Tops Q2 EPS by 7c
-
AstraZeneca (AZN) Tops Q1 EPS by 2c; Offers FY16 Outlook
-
AstraZeneca (AZN) Tops Q4 EPS by 6c; Issues FY16 Outlook, Expected FX Impact
-
AstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
-
AstraZeneca (AZN) Tops Q3 EPS by 26c; Boosts FY15 EPS Growth Outlook
-
AstraZeneca (AZN) Misses Q3 EPS by 9c
-
AstraZeneca (AZN) Tops Q2 EPS by 21c; Boosts Outlook
-
Pfizer (PFE) Pulls Offer for AstraZeneca (AZN)
-
AstraZeneca (AZN) Rejects Pfizer's (PFE) Final Proposal
-
Pfizer (PFE) Increases Offer for AstraZeneca (AZN)
-
AstraZeneca (AZN) Updates on Growth Targets; Sees Annual Revs of $45B+ by FY23
-
AstraZeneca (AZN) Rejects Latest Pfizer (PFE) Offer
-
Pfizer (PFE) Increases Offer for AstraZeneca (AZN) to GBP50/Share
-
Pfizer, Inc. (PFE) Confirms AstraZeneca (AZN) Takeover Approach
-
AstraZeneca (AZN) Tops Q4 EPS by 1c
-
AstraZeneca (AZN) Misses Q3 EPS by 6c
-
AstraZeneca (AZN) Tops Q2 EPS by 4c
Back to AZN Stock Lookup